Cao Y
Laboratory of Angiogenesis Research, Microbiology and Tumor Biology Center, Karolinska Institute, S-171 77, Stockholm, Sweden.
Haematologica. 1999 Jul;84(7):643-50.
The discovery of specific endothelial inhibitors such as angiostatin and endostatin not only increases our understanding of the functions of these molecules in the regulation of physiological and pathological angiogenesis, but also provides an important therapeutic strategy for cancer treatment. Recent studies have demonstrated that the angiostatin protein significantly suppresses the growth of a variety of tumors in mice. However, the dosages of angiostatin protein used in these animal studies seem to be too high for clinical trials. In addition, repeated injections and long-term treatment with angiostatin are required to reach its maximal antitumor effect. In this article, I will discuss several alternative approaches that may become feasible to move angiostatin therapy from animal experiments into the clinic. In particular, I will emphasize the therapeutic potentials of angiostatin gene therapy and more potent angiogenesis inhibitors that are related to angiostatin.
血管抑素和内皮抑素等特异性内皮抑制剂的发现,不仅增进了我们对这些分子在生理和病理血管生成调节中功能的理解,也为癌症治疗提供了重要的治疗策略。最近的研究表明,血管抑素蛋白能显著抑制小鼠体内多种肿瘤的生长。然而,这些动物研究中使用的血管抑素蛋白剂量对临床试验来说似乎过高。此外,需要重复注射和长期使用血管抑素才能达到其最大抗肿瘤效果。在本文中,我将讨论几种可能使血管抑素治疗从动物实验走向临床可行的替代方法。特别是,我将强调血管抑素基因治疗以及与血管抑素相关的更有效的血管生成抑制剂的治疗潜力。